Impact of GSK-3β and CK-1δ on Wnt signaling pathway in alzheimer disease: A dual target approach

V Sharma, PC Sharma, V Yadav, RK Tonk, J Majeed… - Bioorganic …, 2024 - Elsevier
Alzheimer's disease (AD) is an enigmatic neurological illness that offers few treatment
options. Recent exploration has highlighted the crucial connection of the Wnt signaling …

Advancements in nose-to-brain drug targeting for Alzheimer's disease: a review of nanocarriers and clinical insights

K Komal, R Ghosh, D Sil, R Sharma, S Kumar… - …, 2025 - Springer
Alzheimer's disease (AD) is a type of neurodegenerative disease that describes cognitive
decline and memory loss resulting in disability in movement, memory, speech etc. Which first …

Current advances in our understanding of circular RNA (circRNA) in Alzheimer's disease (AD); the potential utilization of synthetic circRNAs as a therapeutic strategy …

Y Zhao, VR Jaber, WJ Lukiw - Frontiers in Drug Discovery, 2022 - frontiersin.org
Circular RNAs (circRNAs) represent a large, naturally occurring family of extremely stable
single-stranded RNAs (ssRNAs) with covalently linked 3′ and 5′ ends. Traditional …

Reconsidering red blood cells as the diagnostic potential for neurodegenerative disorders

S Yadav, Deepika, K Moar, A Kumar, N Khola… - Biology of the …, 2024 - Wiley Online Library
Abstract Background Red blood cells (RBCs) are usually considered simple cells and
transporters of gases to tissues. Hypothesis However, recent research has suggested that …

TDP-43 as a potential retinal biomarker for neurodegenerative diseases

M Glashutter, P Wijesinghe… - Frontiers in Neuroscience, 2025 - frontiersin.org
TDP-43 proteinopathies are a spectrum of neurodegenerative diseases (NDDs)
characterized by the pathological cytoplasmic aggregation of the TDP-43 protein. These …

α-synuclein as an emerging pathophysiological biomarker of Alzheimer's disease

MF Beatino, C De Luca, N Campese… - Expert Review of …, 2022 - Taylor & Francis
Introduction α-syn aggregates represent the pathological hallmark of synucleinopathies as
well as a frequent copathology (almost 1/3 of cases) in AD. Recent research indicates a …

SIMOA Diagnostics on Alzheimer's Disease and Frontotemporal Dementia

A Chatziefstathiou, S Canaslan, E Kanata, K Vekrellis… - Biomedicines, 2024 - mdpi.com
Background: Accurate diagnosis of Alzheimer's disease (AD) and frontotemporal dementia
(FTD) represents a health issue due to the absence of disease traits. We assessed the …

[HTML][HTML] Use of Laughter for the Detection of Parkinson's Disease: Feasibility Study for Clinical Decision Support Systems, Based on Speech Recognition and …

M Terriza, J Navarro, I Retuerta, N Alfageme… - International journal of …, 2022 - mdpi.com
Parkinson's disease (PD) is an incurable neurodegenerative disorder which affects over 10
million people worldwide. Early detection and correct evaluation of the disease is critical for …

Brain Network Dynamics and Multiscale Modelling of Neurodegenerative Disorders: A Review

H Shaheen, R Melnik - IEEE Access, 2025 - ieeexplore.ieee.org
It is essential to understand the complex structure of the human brain to develop new
treatment approaches for neurodegenerative disorders (NDDs). This review paper …

Exploring cognitive and neuroimaging profiles of dementia subtypes of individuals with dementia in the Democratic Republic of Congo

J Ikanga, SS Patel, M Schwinne… - Frontiers in Aging …, 2025 - search.proquest.com
Objective: The 2024 Alzheimer's Association (AA) research diagnostic criteria for
Alzheimer's Disease (AD) considers fluid biomarkers, including promising blood-based …